Edgestream Partners L.P. bought a new stake in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 190,714 shares of the company's stock, valued at approximately $2,739,000. Edgestream Partners L.P. owned about 0.16% of 10x Genomics at the end of the most recent reporting period.
A number of other hedge funds have also recently bought and sold shares of the stock. Capital Performance Advisors LLP bought a new stake in shares of 10x Genomics during the third quarter valued at approximately $35,000. Blue Trust Inc. boosted its stake in 10x Genomics by 73.1% during the fourth quarter. Blue Trust Inc. now owns 3,075 shares of the company's stock worth $44,000 after buying an additional 1,299 shares in the last quarter. Sound Income Strategies LLC increased its holdings in 10x Genomics by 65.2% in the 4th quarter. Sound Income Strategies LLC now owns 3,370 shares of the company's stock valued at $48,000 after buying an additional 1,330 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of 10x Genomics in the 4th quarter valued at $52,000. Finally, Venturi Wealth Management LLC raised its stake in shares of 10x Genomics by 1,108.9% in the 3rd quarter. Venturi Wealth Management LLC now owns 2,442 shares of the company's stock valued at $55,000 after buying an additional 2,240 shares in the last quarter. 84.68% of the stock is owned by institutional investors.
10x Genomics Price Performance
Shares of TXG stock traded down $0.97 during trading hours on Thursday, reaching $9.88. 2,223,655 shares of the company were exchanged, compared to its average volume of 2,808,281. 10x Genomics, Inc. has a fifty-two week low of $9.27 and a fifty-two week high of $39.30. The stock's fifty day moving average is $13.41 and its two-hundred day moving average is $16.14. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -6.50 and a beta of 1.93.
10x Genomics (NASDAQ:TXG - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. On average, research analysts anticipate that 10x Genomics, Inc. will post -1.43 earnings per share for the current year.
Insider Activity at 10x Genomics
In other 10x Genomics news, insider Benjamin J. Hindson sold 4,573 shares of the firm's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $11.07, for a total value of $50,623.11. Following the transaction, the insider now directly owns 335,324 shares of the company's stock, valued at approximately $3,712,036.68. This trade represents a 1.35 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Alan Mateo bought 40,000 shares of the company's stock in a transaction on Friday, February 21st. The shares were acquired at an average price of $11.14 per share, with a total value of $445,600.00. Following the transaction, the director now directly owns 61,691 shares in the company, valued at approximately $687,237.74. The trade was a 184.41 % increase in their position. The disclosure for this purchase can be found here. 10.03% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
A number of analysts recently weighed in on the stock. UBS Group lowered their target price on shares of 10x Genomics from $20.00 to $14.00 and set a "neutral" rating on the stock in a research note on Thursday, February 13th. Citigroup lowered their price objective on 10x Genomics from $20.00 to $15.00 and set a "buy" rating on the stock in a research note on Tuesday, March 4th. Stifel Nicolaus cut their target price on 10x Genomics from $21.00 to $18.00 and set a "buy" rating for the company in a research report on Thursday, February 13th. Canaccord Genuity Group lowered their price target on 10x Genomics from $20.00 to $18.00 and set a "buy" rating on the stock in a research report on Thursday, February 13th. Finally, Barclays cut their price objective on 10x Genomics from $19.00 to $18.00 and set an "overweight" rating for the company in a report on Monday, February 10th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $20.21.
Check Out Our Latest Analysis on TXG
10x Genomics Profile
(
Free Report)
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.
Featured Stories
Before you consider 10x Genomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 10x Genomics wasn't on the list.
While 10x Genomics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
